The Role of Serum Adipokines in Predicting Response to Neoadjuvant Therapy in Patients With Rectal Cancer

Istanbul Training and Research Hospital

Status: Enrolling

Conditions: Rectal Cancer Stage III

Treatments: Diagnostic Test: serum adipokines

Study type: Observational

Funder types: Other

Identifiers

NCT04598984

2506

Details and patient eligibility

About

It has been shown that adipokines (resistin, leptin, adiponectin) secreted from adipose tissue and proinflammatory cytokines such as IL-6, TNF-a are associated with the risk of developing colorectal cancer. However, the role of these factors in predicting clinical response to neoadjuvant therapy in rectal cancers is unknown. In this study, the role of serum adipokine levels before neoadjuvant therapy in predicting clinical response in patients with rectal cancer is investigated. For this purpose, blood will be drawn from patients with rectal cancer who will receive neoadjuvant therapy, serum adipokines will be studied and clinical response to neoadjuvant therapy will be compared.

Enrollment: 60 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• All patients with locally advanced rectal cancer

Exclusion criteria

• below 18 years old
• patients who did not received neoadjuvant therapyAll

Trial design

60 participants in 2 patient groups

Low levels of serum adipokines

Treatment:

Diagnostic Test: serum adipokines

High levels of serum adipokines

Treatment:

Diagnostic Test: serum adipokines